Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣

Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide.

We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform.

Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide.

- Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) 

- We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply.

Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development.

We are currently envisaging clinical collaborations.

Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.